Furthermore, the use of specificanti-cancer therapies, such as selective estrogen receptor modulators in breastcancer and androgen deprivation therapy in prostate cancer, could lead to elevatedbleeding risk[12,13]. Here, ESR1 is linked to prostate carcinoma.